Quarterly report pursuant to Section 13 or 15(d)

GOING CONCERN (Details Narrative)

v3.19.3.a.u2
GOING CONCERN (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
May 06, 2019
Oct. 29, 2018
May 25, 2017
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Accumulated deficit       $ (18,556,562)   $ (18,262,136)  
Cash       4,931 $ 3,878 $ 89 $ 142
Principal and interest       1,458,037      
Net cash used for operating activities       $ (168,908) $ (57,564)    
Increase in unauthorized shares, description     The Company increased their number of unauthorized shares from 100,000,000 to 800,000,000 as they hope to raise additional capital through the sale of its equity securities, through an offering of debt securities        
First Capital Holdings [Member] | Letter of Intent [Member] | Convertible Notes [Member]              
Debt, maturity terrm   2 years          
Business acquisition, debt instrument, conversion price   $ 2.00          
Business acquisition, consideration transferred, shares issued, percentage   60.00%          
Business acquisition, agreeement terms, reverse stock split, description   The Company completing a reverse stock split of its common stock such that approximately 8,000,000 shares will be outstanding immediately prior to closing the transaction with no convertible instruments other than as set forth herein.          
Business acquisition, debt, outstanding   $ 125,000          
IDTEC, LLC [Member] | Asset purchase agreement [Member]              
Business acquisition, shares consideration 12,000,000            
Business acquisition, consideration, share price $ 0.00001            
Business acquisition, shares issuable, description The total number of shares of TransBiotec’sTransBiotec’s $0.00001 par value common stock issued and outstanding following a tentative closing date of January 31, 2020 shall not exceed 20 million (20,000,000) shares (on a fully dilated basis).